Wells Fargo & Company Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Guardant Health (NASDAQ:GH) had its price target increased by investment analysts at Wells Fargo & Company from $120.00 to $125.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 21.24% from the stock’s previous close.

Several other research firms also recently issued reports on GH. Leerink Partners upped their price objective on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. BTIG Research upped their price target on Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research report on Thursday, January 22nd. Finally, Citigroup lifted their price target on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday. Twenty-one equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $117.43.

Guardant Health Stock Down 3.1%

Shares of NASDAQ GH opened at $103.10 on Friday. Guardant Health has a 12-month low of $34.88 and a 12-month high of $120.74. The firm’s 50-day simple moving average is $106.69 and its 200 day simple moving average is $86.22. The company has a market cap of $12.99 billion, a price-to-earnings ratio of -31.15 and a beta of 1.63.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. During the same period in the previous year, the company posted ($0.62) earnings per share. The company’s revenue was up 39.4% on a year-over-year basis. On average, equities analysts expect that Guardant Health will post -2.9 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.05, for a total value of $10,505,000.00. Following the sale, the chief executive officer directly owned 168,223 shares in the company, valued at $17,671,826.15. This trade represents a 37.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CTO Darya Chudova sold 5,451 shares of Guardant Health stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $104.04, for a total transaction of $567,122.04. Following the transaction, the chief technology officer directly owned 7,012 shares in the company, valued at $729,528.48. The trade was a 43.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 434,511 shares of company stock worth $45,580,887 over the last quarter. Insiders own 6.10% of the company’s stock.

Institutional Trading of Guardant Health

A number of large investors have recently made changes to their positions in GH. Alyeska Investment Group L.P. acquired a new stake in Guardant Health during the 3rd quarter worth $114,421,000. Price T Rowe Associates Inc. MD raised its position in shares of Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares during the period. Norges Bank bought a new position in shares of Guardant Health during the 4th quarter valued at about $128,499,000. Franklin Resources Inc. lifted its holdings in shares of Guardant Health by 78.2% during the 2nd quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after purchasing an additional 1,018,144 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Guardant Health by 27.3% in the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock valued at $185,184,000 after purchasing an additional 763,834 shares during the period. Institutional investors own 92.60% of the company’s stock.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.